SuperworthIronwood Pharmaceuticals IRWD
- Market cap
- $571.7M
- PE
- 4.5×
- 7y median 14.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.5×
- EV/EBIT
- 3.5×
- Revenue, 12 months
- $389.3M
- +26% on a year ago
- Net margin
- 33.4%
- Free cash flow yield
- n/m
- not a meaningful number
Ironwood Pharmaceuticals trades at 4.5× trailing earnings, cheaper than 100% of the last ten years. Revenue was $389.3M over the last twelve months, up 26% on a year earlier with a 33% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $113.7M+5% | $117.6M+10% | $74.9M−28% | $94.4M−12% | $91.6M−20% | $90.5M−23% | $41.1M−45% | $85.2M−10% | $122.1M+33% | $47.7M−47% | $106.5M+159% | $113M+33% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $33M+186% | $35.7M+242% | $25.8M+101% | $30.4M−12% | $29.8M−10% | $25.4M−29% | $27.4M+6% | $23.4M−23% | $22.5M−25% | $21.9M−14% | $21.9M−20% | $22.4M−4% |
| SG&A | $36M+26% | $38.7M+36% | $37.6M+21% | $37M−30% | $36.1M+0% | $33.6M−13% | $24.3M−36% | $16.8M−55% | $21.9M−39% | $19.3M−43% | $12M−50% | $11.3M−33% |
| $40M−42% | $37.6M−45% | $11M−82% | $25M | $25.6M−36% | $31.5M−16% | −$29.1M | $45.3M+82% | $75.5M+194% | $6.8M−78% | $72.6M | $79.3M+75% | |
| Interest expense | $9.8M+546% | $8.4M+452% | $7.2M+374% | $7.5M+306% | $9.4M−4% | $8.9M+6% | $8.1M+12% | $8.4M+12% | $8.4M−11% | $7.9M−12% | $9.1M+13% | $7.2M−14% |
| Pre-tax income | $31.9M−54% | $30.4M−58% | $5M−93% | $18.9M | $17.4M−46% | $24M−21% | −$36.3M | $37.8M+100% | $68M+292% | $455K−98% | $65.2M | $73.7M+95% |
| $18M−8% | $32.1M+37% | $9.1M−55% | $19.7M+49% | $13.7M−24% | $21.7M−32% | $1.1M−88% | $14.2M−28% | $27.9M+104% | $2.7M−87% | $24.4M+2090% | $22.4M+58% | |
| Net income | $15.3M−70% | −$1.1M | −$4.2M | −$860K−100% | $3.6M−76% | $2.3M | −$37.4M+798% | $23.6M | $40.1M+999% | −$2.3M | $40.8M | $51.3M+117% |
| $0.09−68% | −$0.01 | −$0.03 | −$0.01−100% | $0.02−78% | $0.01 | −$0.23+667% | $0.14 | $0.23+1050% | −$0.01 | $0.24 | $0.31+121% | |
| 186.9M+1% | 156M−16% | 157.7M−16% | 159M+2% | 160.2M−14% | 160.9M+3% | 161M+2% | 176.8M+11% | 177.8M+11% | 162.4M+1% | 166.7M+4% | 167.2M−6% |
Gross profit: 27 periods, Q1 FY13 to Q4 FY20: not printed by the filing, worked out from its own lines.
Net income: 20 periods, Q1 FY12 to Q1 FY17: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY10 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY17 to Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| Peer median | $789.2M | 12.8× | 15.7× | 1.7× | +6% | 11.2% |
More on Ironwood Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 168Healthcare stocks with the lowest PE ratio
- #7of 202Healthcare stocks with the lowest EV/EBIT
- #3of 41Large drugmakers with the lowest PE ratio
- #5of 48Large drugmakers with the lowest EV/EBIT
- #10of 84Large drugmakers with the highest profit margins
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .